In response to the U.S. Food and Drug Administration’s requests for public comment regarding medical product manufacturer communications, a pair of letters from AHIP Executive Vice Presidents Richard Bankowitz and Matthew Eyles commended the agency for conducting a comprehensive review and providing clarification regarding acceptable forms of communication by manufacturers. The letters emphasized the importance of communication between medical product manufacturers and health plans along with the significant role played by the FDA regarding standards for safety, efficacy, and the supporting evidence. ... |